A CRA expert was retained to analyze class certification issues relating to allegations that a pharmaceutical product was marketed for off-label uses and caused direct and indirect purchasers to pay for billions of dollars unnecessarily. The expert found that differences among putative class members would necessitate individualized inquiries into whether the alleged conduct caused each any economic damages. The judge denied class certification, citing the CRA expert’s opinion in support of several key points.
IP Literature Watch: September 2022
Among the pieces featured in this month’s IP Literature Watch are a paper discussing the licensing of 5G SEPs by automotive manufacturers; an essay exposing...